Summary of Study ST002920

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001814. The data can be accessed directly via it's Project DOI: 10.21228/M87D9M This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST002920
Study Title	Possible PPARG-independent effects of DINCH and MINCH on central carbon metabolism
Study Summary	In the third part of the project, we investigated the PPARG-independent effects of DINCH and MINCH on the central carbon metabolism of human SGBS cells. SGBS preadipocytes were treated for 12 days with 10 µM MINCH, 10 µM DINCH, or rosiglitazone in the presence of the PPARG inhibitor GW9662. Irreversible blocking of PPARG was achieved by incubating cells with 10 µM GW9662 1 hour before treatment and maintaining a regular treatment interval of 2 days. In conclusion, although the PPARG inhibitor GW9662 greatly reduced the effects of MINCH and rosiglitazone, slightly increased lipid accumulation along with increased lactate secretion and increased concentrations of pyruvate cycle metabolites were consistently induced by MINCH treatment even after PPARG inhibition. This suggests that MINCH exerts its effects on lipid accumulation and central carbon metabolism at least in part via a PPARG-independent mechanism.
Institute	Helmholtz Centre for Environmental Research
Last Name	Engelmann
First Name	Beatrice
Address	Permoserstr. 15
Email	beatrice.engelmann@ufz.de
Phone	00493412351099
Submit Date	2023-10-08
Raw Data Available	Yes
Raw Data File Type(s)	wiff
Analysis Type Detail	LC-MS
Release Date	2023-11-01
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR003042
Treatment Summary:	SGSB preadipocytes were maintained at 37°C and 5% CO2 in 95% humidity. To assess the PPARG-independent effects of DINCH and MINCH on central carbon metabolism, SGBS preadipocytes were exposed to differentiation media containing DINCH (10 µM DINCH+GW) or MINCH (10 µM MINCH+GW) supplemented with the PPARG antagonist GW9662 for 12 days. Irreversible blocking of PPARG prior to treatment was achieved by adding the antagonist 1 hour before the addition of the respective chemical. For comparison, SGBS cells were treated with rosiglitazone (d0-d4) as in the standard protocol but in the presence of GW9662 (Rosi+GW), and SGBS cells were treated with GW9662 only for 12 days (Ctrl+GW). During differentiation, a final concentration of 0.01% (v/v) MeOH and 0.02% (v/v) DMSO was added to all differentiation media. Continuous exposure was mimicked by replacing the cell culture medium every other day. Each treatment was performed in four biological replicates (n=4).

Treatment ID:

TR003042

Treatment Summary:

SGSB preadipocytes were maintained at 37°C and 5% CO2 in 95% humidity. To assess the PPARG-independent effects of DINCH and MINCH on central carbon metabolism, SGBS preadipocytes were exposed to differentiation media containing DINCH (10 µM DINCH+GW) or MINCH (10 µM MINCH+GW) supplemented with the PPARG antagonist GW9662 for 12 days. Irreversible blocking of PPARG prior to treatment was achieved by adding the antagonist 1 hour before the addition of the respective chemical. For comparison, SGBS cells were treated with rosiglitazone (d0-d4) as in the standard protocol but in the presence of GW9662 (Rosi+GW), and SGBS cells were treated with GW9662 only for 12 days (Ctrl+GW). During differentiation, a final concentration of 0.01% (v/v) MeOH and 0.02% (v/v) DMSO was added to all differentiation media. Continuous exposure was mimicked by replacing the cell culture medium every other day. Each treatment was performed in four biological replicates (n=4).